Awarded TED · Source · Language: Deutsch

Germany · Medical equipment, pharmaceuticals and personal care products

Official title · Deutsch

Arzneimittelrabattvertrag zu den Arzneimitteln Advate (B02BD02),Recombinate (B02BD02),Rixubis (B02BD04),Feiba (B02BD03),Immunate (B02BD06),Immuseven (B02BD05),Adynovi (B02BD02),Veyvondi (B02BD10)

AOK Sachsen - Anhalt · Germany

View notices under this name

Official summary · Deutsch

What is being procured?

Die AOK Sachsen-Anhalt hat zur Behandlung der Hämophilie mit dem Hersteller der Arzneimittel Advate (B02BD02), Recombinate (B02BD02), Rixubis (B02BD04), Feiba (B02BD03), Immunate (B02BD06), Immunine (B02BD04), Immuseven (B02BD05), Adynovi (B02BD02) und Veyvondi (B02BD10) zum 01.09.2026 einen Vertrag gem. § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V abgeschlossen.

Deadline Not announced
Estimated valueNot announced
PublishedSep 3, 2026
Open official notice ↗

Notice history

Procurement timeline

Follow the main stages and updates linked to this procurement procedure.

No other related notice has been identified yet.

  1. Result notice Current notice

    · TED 607562-2026

    Open official notice ↗

Data is restructured for easier reading. The official notice and procurement documents always prevail.

Source and reliability

TED · 607562-2026. Checked on Sep 4, 2026, 8:05 AM.

Data is restructured for easier reading. The official notice and procurement documents always prevail.

Report an error by email